SBIR/STTR Research Award

Aminopiperidines as novel anti influenza agents

Award identifier 069fc7d3d75205904adfd8a5a485740a3da0652b6795f0b5aa6122c81d9af805Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$396,096

Program and phase

STTR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Chicago Biosolutions, Inc.
Proposal award date
2016-06-01
Contract end date
2019-05-31
UEI
KJL4YQ7KSEK9
Solicitation number
PA15-270
Topic code
NIAID

Research abstract

Influenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vaccination has limited effectiveness in treatment of immunocompromised patients and its effectiveness is also limited during a pandemic The current therapeutic options for flu infections are all based on the NA inhibitors NAIs while the influenza M ion channel blockers amantadine and rimantadine are not recommended anymore since all the circulating influenza strains are resistant to them However the rapid emergence of the NAI resistant strains of influenza A viruses strongly suggest that NAIs alone may not be sufficient as an effective means of the anti flu therapies and thus new treatment options targeting the other viral host factors are urgently needed This application defines a plan to develop potent small molecule inhibitors which block entry of influenza A viruses We have identified compounds that inhibit entry of infectious influenza A viruses IC values M These hit compounds exhibit selectivity for H N and H N entry The overall objective of this Phase I application is to develop these inhibitors as potential anti flu therapeutics This application will focus on the following three specific aims Synthesize structurally diverse analogs of the anti flu CBS hit series based on structure activity relationships SARs to improve potency and selectivity Validate the lead inhibitor candidates in the infectious assay and investigate the mechanism of action MOA of the inhibitors Select flu inhibitors with in vitro ADME properties suitable for i v and oral dosing Project Narrative This project is to discover and develop small molecule entry inhibitors for influenza viral infection The proposed research will help to develop potential antiviral therapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2016–2022). Reported award amounts total $8,762,050. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.